Candida auris is an emerging fungal pathogen that has become a critical global health concern due to its high antifungal resistance and potential to cause nosocomial outbreaks. Since its initial identification in Japan in 2009, C. auris has spread rapidly, posing significant treatment challenges across various healthcare settings worldwide. The biofilm formation ability of C. auris enhances its resilience against disinfectants and antifungal agents, complicating infection control in healthcare environments. This consensus report, developed with the collaboration of several Turkish medical specialty societies, including the Turkish Society of Infectious Diseases and Clinical Microbiology Specialty (EKMUD), the Turkish Society of Anesthesiology and Reanimation (TARD), the Turkish Intensive Care Society (TYBD), the Infectious Diseases – International Research Initiative (ID-IRI), the Clinical Microbiology Specialist Society (KLIMUD), the Turkish Microbiology Society (TMC), and the Public Health Institution of Türkiye (PHIT) under the Ministry of Health, provides a comprehensive overview of C. auris and its’ management. The report focuses on the epidemiology, antifungal resistance mechanisms, recommendations for diagnostic and therapeutic challenges, infection control and prevention measures and surveillance of C. auris. This consensus report aims to establish standardized diagnostic protocols, improve national surveillance systems, and promote effective infection control measures to mitigate C. auris related health risks in Türkiye. It also offers comprehensive national recommendations and addresses the need for inter-institutional collaboration, improve public health, and strengthen the healthcare response to this pathogens.
Aims:This study aimed to investigate the effectiveness of immature granulocyte count and the percentage of immature granulocytes in predicting mortality in patients aged 80 years and older (octogenarians) in intensive care units. Methods: This retrospective study included 333 patients aged 80 years and older who were followed up in the intensive care unit. Demographic data, laboratory values, clinical outcomes, and mortality status were recorded. The data were evaluated in two groups: survivors and deaths. Differences between the groups were statistically analyzed and compared. Results: While the Glasgow Coma Scale(GCS) was lower in the mortality group, the Acute Physiology and Chronic Health Evaluation II(APACHE II) and Sequential Organ Function Assessment(SOFA) scores were higher than in the survivors (p<0.001 for all). C reactive protein (CRP), neutrophil-to-lymphocyte ratio, and lactate values were significant markers for mortality prediction. No significant difference was found for immature granulocyte count and percentage when the groups were compared. APACHE II and SOFA scores had the highest discriminatory power in predicting mortality, with the area under the curve= 0.74. Conclusion: In octogenarian patients followed up in the intensive care unit, we found that the number and percentage of immature granulocytes was not an effective biomarker for predicting mortality despite its cheap and easy use. In the future, more comprehensive studies may show the importance of immature granulocytes.
12 February 2024 in Eurasian Journal of Anesthesiology and Intensive Care
Aims: This study compares bupivacaine – lidocaine and levobupivacaine – lidocaine administrations in terms of initiation and duration of motor and sensorial blockage, total number of additional analgesic applications, analgesic amount consumed in 24 hours, side-effects and hemodynamic effects in continuous axillary brachial pleksus block in hand and forearm surgery. Methods: Thirty ASA I & II physical status patients, scheduled hand or forearm surgery were enrolled for of the two groups in a randomized study. Axillary catheter duly placed in both group with appropriate guided techniques. Patients in group B received 0. 5% bupivacaine 20 ml + 2% lidocaine 20 ml and group L received 0. 5% levobupivacaine 20 ml + 2% lidocaine 20 ml through the axillary catheter. Initiation and duration of motor and sensorial block, total number of additional analgesic applications and analgesic amount consumed in postoperative 24 hours were recorded. Pre-block, peri-operative and post-operative blood pressures and heart beat rates were also recorded. Block application duration, operation duration, tourniquet duration and demographic data of patients (age, sex, weight, and length) were recorded. Demanded and applied analgesic doses by the patient controlled analgesia devices, side effects and complications were also recorded. Results: There was no statistically significant difference between two groups in terms of initiation and duration of motor and sensorial block, amount of analgesic consumed in 24 hours, demanded and applied analgesic doses by the patient controlled analgesia devices and hemodynamic data (p>0. 05). There is a mild and positive relation between block application duration and patient weight. (p=0. 014; r=0. 444) Conclusion: Both bupivacaine+lidocaine and levobupivacaine+lidocaine combinations can safely be used in axillary continuous brachial plexus block without any difference in terms of initiation and duration of block, total analgesic amount consumed. Their duration of action and effect on hemodynamic responses are similar.